# Virtual Biotech Session
**Run:** 20261020-085513-evaluate-the-therapeutic-candida-a03f0a23
**Session:** f528cbed-f3bf-40b4-85f8-e31264fc6ba0
**Started:** 2026-10-20T08:55:36.021689
**Last updated:** 2026-10-20 11:54:45
**Total cost:** $28.58

## Turn 1
**User:** Evaluate the therapeutic candidacy of B7-H3 (CD276) in lung cancer. Scope the disease strictly to lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) -- not NSCLC broadly, not other lung histologies. General web search and web scraping are disabled for this study; use only the configured database MCP servers (Open Targets, CELLxGENE Census, etc.) and your own prior knowledge, clearly labeled as such when you rely on it. Spatial transcriptomics / Visium analysis is out of scope for this pass.

**CSO:** I'll orchestrate this as a full therapeutic-candidacy evaluation across the Target ID, Safety, Modality, and Clinical divisions, scoped strictly to LUAD and SCLC. First, let me load the run-organization contract and inspect the run directory.

The run is fresh and the provenance server is configured. I'll record the analysis plan (7 parallel evidence streams, then modality ranking, then QA).

Plan recorded (9 steps). I'm launching seven parallel evidence streams across the Target ID, Safety, Clinical, and Modality divisions; the modality ranker and scientific reviewer will follow once their upstream inputs exist.

All seven parallel streams returned. The picture is already differentiated: SCLC has substantial clinical investment (ADCs, 6 Phase 3 trials) while LUAD has zero B7-H3-specific trials; genetic causality is absent in both; and single-cell data show CD276 transcript is highest in stromal cells, which cuts against a simple tumor-cell-selectivity story. I'm now sending the biology and clinical landscape to the modality ranker.

The modality ranker converges on ADC-first, with SCLC as GO and LUAD as conditional/no-go. Before synthesizing, I'm sending all eight outputs to the scientific reviewer to stress-test scope, data support, and the two places the evidence could be over-read: the stromal-vs-malignant expression pattern and the "zero LUAD trials" claim.

The reviewer verified the headline numbers but flagged three material corrections: the single-cell "2× in 3/3 donor pairs" claim is wrong (individual ratios 3.26, 3.40, 1.09 — ≥2× in only 2/3), the SCLC "GO" is premature because feasibility is established but efficacy is not, and the LUAD "no-go" conflates absence of LUAD-specific trials with absence of LUAD evidence. I'm sending targeted revisions to those three specialists before synthesizing.

The modality revision succeeded; the single-cell and safety revisions hit transient 403 errors before doing any work. I'm retrying those two — no analysis changes, just the reviewer's corrections.

All corrections are in. I'm now reconciling the exact artifact paths from the run manifest before filing the claim-evidence objects.

All 17 claims are filed and evidence-verified. I'm writing the run report, then I'll give you the decision summary.

## Bottom line

B7-H3 is a **credible surface-antigen target for payload delivery in SCLC, but not a validated one**. It is **not a defensible signalling target** in either histology, and **LUAD should be deprioritized on strategic grounds, not because the biology is disqualifying**. ADC is the modality of choice in both indications.

The scientific reviewer caught two overstatements before synthesis — a single-cell "2× tumor/normal in 3/3 donors" claim that was actually ≥2× in only 2/3, and an unconditional SCLC "GO" that is really feasibility-only. Both were corrected in the underlying artifacts.

## What the evidence shows

**Target biology (Modality division).** CD276 is a type I surface antigen with strong antibody tractability, no small-molecule tractability, and no viable PROTAC route[[claim:C1]]. No canonical B7-H3 receptor is established in the queried interaction data, and co-inhibitory versus co-stimulatory function remains unresolved[[claim:C14]]. The therapeutic rationale must therefore be payload delivery or cell depletion, not pathway inhibition.

**Genetic and functional support (Target ID division).** Human genetics is absent for these indications: 0/8 queried LUAD/SCLC GWAS contained a CD276-locus credible set, and 0/67 L2G predictions derive from LUAD or SCLC studies[[claim:C3]]. CD276 is also non-essential in both histologies — mean CRISPR gene effect −0.230 in 46 LUAD lines (2.2% essential) and −0.204 in 25 SCLC lines (0% essential), with no lineage selectivity[[claim:C2]]. This rules out a signalling-inhibitor monotherapy but does not undercut an ADC.

**Expression and selectivity (Target ID division).** In dissociated tumor transcriptomes, CD276 is higher in fibroblasts and macrophages than in malignant/epithelial cells in **both** indications (LUAD fibroblast 75.9 vs malignant 23.6 CPM; SCLC fibroblast 68.1 vs epithelial 28.5 CPM)[[claim:C4]]. LUAD tumor epithelium was higher than paired adjacent normal in 3/3 donors, but reached ≥2× in only 2/3 (ratios 3.26, 3.40, 1.09) and was not significant at n=3[[claim:C5]]. Normal-tissue expression is broad and low-to-moderate, highest in skin/kidney and near-zero in hematopoietic tissue; normal lung is 1,683 TPM by bulk RNA (HPA level 4) but only protein level 2 and 13.9 CPM at cell level[[claim:C6]]. The key caveat: these are transcripts, not surface protein. The stromal signal is a shared antigen-sink/bystander concern, not a LUAD-specific disqualifier.

**Clinical precedence (Clinical Officers).** There are **zero LUAD-specific B7-H3 trials**, versus **26 SCLC-contributing trials including 6 Phase 3 trials across 4 molecules**, overwhelmingly ADCs[[claim:C7]]. LUAD patients are nonetheless eligible in at least three nonsquamous-NSCLC trials (NCT07464327, NCT06780085, NCT07824882), so absence of a LUAD-specific trial is not absence of LUAD evidence[[claim:C16]]. Efficacy is unproven: only 4/43 curated trials have posted results, the sole SCLC-specific posted result is MGC018 ORR 0/9 (n=9), and the completed Phase 3 ARTEMIS-008 has no posted results[[claim:C8]][[claim:C9]].

**Safety (Safety division).** CD276 is moderately LoF-tolerant (o/e 0.667); target-level OpenFDA AEs, mouse phenotypes, and PGx records are absent, and there are no FDA records for I-DXd or MGC018 — evidence gaps, not clean safety[[claim:C10]]. Mouse CD276 identity is only 52.4% versus macaque 94.6%, making mouse a poor toxicology species[[claim:C17]]. The dominant ADC risk is payload-level — ILD/pneumonitis and myelosuppression — not target biology, and prior thoracic radiation or checkpoint pneumonitis narrows the pulmonary margin[[claim:C11]].

## Recommendation

| Indication | Decision | Modality |
|---|---|---|
| **SCLC** | **Staged GO** (composite 4.20) — conditional on a positive class-level Phase 3 readout and a differentiated profile | B7-H3 ADC |
| **LUAD** | **Deprioritized** (ADC composite 2.90; clinical precedence 1/5) | ADC internally ranked first, but no LUAD-specific precedence |

ADC ranks first in both indications; T-cell engager is the backup, CAR-T and radioimmunotherapy are research options[[claim:C12]]. A me-too B7-H3 ADC is not investable given the crowded SCLC class; differentiation must come from safety, a novel payload/linker, rational combination (e.g., DLL3 TCE or PD-L1), or a biomarker-defined population.

**Decisive de-risking experiment:** paired quantitative surface B7-H3 density plus internalization in patient tumor versus normal lung, with proposed gates of ≥50,000 molecules/cell, tumor/normal ≥3, internalization ≥40%, and ≥30% PDX regression[[claim:C13]]. The external readout to watch is the first Phase 3 OS result for a B7-H3 ADC (ARTEMIS-008 or I-DXd vs physician's choice)[[claim:C9]].

**Material gaps:** tumor/normal surface-protein density, internalization, and shedding are not retrievable from the configured databases; SCLC single-cell data come from one dataset (9 donors); and Tahoe-100M perturbation data were unavailable[[claim:C15]]. These gaps are why the SCLC recommendation is staged rather than unconditional.

The full audited report is at `report/FINAL_REPORT.md`; 17 claim-evidence objects are filed in `evidence/claims.json`.

**Suggested next steps:**
1. **Commission the paired surface-density/internalization study** in ≥20 SCLC and LUAD resections versus normal lung — it resolves the single largest unknown and gates both indications.
2. **Design the SCLC differentiation package** (novel payload/linker or DLL3 TCE/PD-L1 combination) — a me-too ADC has no commercial path in this crowded class.
3. **Set a Phase 3 readout trigger** (ARTEMIS-008 / I-DXd OS) — no SCLC commitment should precede it.
4. **If LUAD remains strategically important, benchmark against TROP2/HER3 ADCs** and define a biomarker niche before any investment.

Would you like me to pursue any of these?

Data/evidence warning: these tools failed during this turn: mcp__functional_genomics__find_drugs_affecting_gene, mcp__functional_genomics__query_drug_perturbation, mcp__disease__search_diseases_by_name, mcp__target__search_targets_by_name, mcp__single_cell__get_anndata, mcp__single_cell__count_cells, mcp__single_cell__get_census_info. Their results cannot support this answer. Any alternative sources must be identified separately; evidence coverage is incomplete.

**Cost:** $28.58 (cumulative: $28.58)
**Agents:** genomics-analyst, single-cell-analyst, functional-genomics-analyst, bio-pathways-ppi-analyst, clinical-trialist, fda-safety-officer, target-biologist, medchem-pharmacologist, scientific-reviewer

### CSO Reasoning
> Let me start by understanding the task. I'm the CSO of The Virtual Biotech. The user wants me to evaluate B7-H3 (CD276) as a therapeutic candidate in lung cancer, specifically LUAD and SCLC. This is a substantial scientific query requiring specialist delegation.
> 
> First, I should invoke the `run-organization` skill as required before my first delegation. Let me do that.
> 
> Also, since this is the first scientific query in a new session, I should consider invoking the Chief of Staff for an intelligence brief. But note: general web search is disabled — the chief-of-staff has web tools? Actually looking at the tools, chief-of-staff has Read, Write, Edit, Glob, Grep, Bash, TodoWrite, Skill, provenance tools — no WebSearch. The system says web search is disabled. The chief-of-staff's brief has a "Recent Context (news/press releases)" component which would require web. So maybe skip or note that. Let me think — the instruction says consider invoking at first scientific query. But with web disabled, its value is limited to "data landscape feasibility". It might still be useful for data landscape. However, it uses Bash and could inspect MCP configs. I think it's reasonable to skip the chief-of-staff given web is disabled, or invoke it for data landscape only. Actually, the guidance says "First SCIENTIFIC query in a new session" is a when-to-invoke. But the core deliverable is the evaluation. I could invoke it briefly to map data landscape. Hmm, but it might waste time. Let me weigh: The query is complex and multi-division. The chief-of-staff could tell me what MCP tools/data are available. But I already have the tool list in my system prompt. I think I can skip it and instead be efficient with specialists. But the guidance says "consider" — not mandatory. Given web is disabled, I'll skip and note why.
> 
> Actually, let me reconsider. The Chief of Staff might have context about the project. But I have the MCP tool list. I'll skip the web-dependent brief and mention it'
> *... [10,259 chars total]*

> Now let me check the MANIFEST and inputs, and see if provenance tools are available. The skill says call mcp__provenance__write_plan. It's not in my listed functions, but maybe it is available. Let me try it. If it errors, I'll adapt.
> 
> First, let me look at the MANIFEST.json and the environment to see what MCP servers are configured. Also read inputs dir (empty). Let me read MANIFEST.json quickly.

> The provenance MCP server is configured. The tools may be available but not listed in my function schema (perhaps the harness exposes them dynamically). Let me try calling mcp__provenance__write_plan. If it fails, I'll know.
> 
> Let me define the plan. Need disease IDs? Specialists can resolve. But I could provide EFO IDs from prior knowledge: LUAD = EFO_0000571 (lung adenocarcinoma); SCLC = EFO_0002618? Let me recall Open Targets. SCLC in Open Targets: EFO_0002618 is "small cell lung carcinoma"? Actually EFO_0002618 might be "small cell lung cancer". I'll let specialists resolve via disease MCP to avoid errors. I'll say "resolve LUAD and SCLC disease IDs via search_diseases_by_name, and restrict to exactly those two".
> 
> Plan steps:
> 
> s1 genomics-analyst: genetic evidence for CD276 (ENSG00000103855) in LUAD and SCLC: GWAS associations, L2G, QTL colocalization, target tractability + prioritisation scores. Note CD276 is not a classic genetically-driven target; interpret accordingly. Expected outputs: csv/parquet + report.
> 
> s2 single-cell-analyst: CD276 expression in LUAD and SCLC tumors vs normal lung, across cell types; include normal organ expression for safety. Use CELLxGENE Census. Must handle cell-type labels. Expected outputs: tables/figures.
> 
> s3 functional-genomics-analyst: DepMap CRISPR dependency of CD276 in LUAD and SCLC cell lines, selectivity vs other lineages; Tahoe-100M perturbation if available (but CD276 itself is not a drug; maybe query drugs affecting CD276 expression). Focus on whether tumor cells depend on CD276 (likely not) and whether expression is retained. Expected outputs.
> 
> s4 bio-pathways-ppi-analyst: Reactome/GO pathways, PPI interactions for CD276, immune checkpoint context, pathway-based on-target safety. Expected outputs.
> 
> s5 clinical-trialist: B7-H3-targeted agents in LUAD/SCLC: ClinicalTrials.gov search, trial phases, agents (ifinatamab deruxtecan, vobramitamab duocarmazine, enoblituzumab, omburtamab, 7-8002?), cB
> *... [6,131 chars total]*

> Plan recorded. Now write inputs/query.txt verbatim? Let me do that, and also create the work directories? Specialists will create their own. The skill says each specialist writes under work/<its name>/. I can let them.
> 
> Let me now dispatch the 7 parallel specialists. I need to write detailed, self-contained prompts. Each should:
> - Invoke evidence-citation skill.
> - Work only with configured MCP servers; no web.
> - Scope strictly LUAD and SCLC.
> - Use work directory path.
> - Register artifacts.
> - Be persistent on code errors (for code-heavy: s2, s3).
> - Return concise summary with artifact paths.
> 
> I need molecular target ID: CD276 = ENSG00000103855. Let me be sure. CD276 (B7-H3) Ensembl: ENSG00000103855. Yes, I'm fairly confident. I'll state it and tell them to verify via search_targets_by_name if needed.
> 
> Disease IDs: instruct to resolve via mcp__disease__search_diseases_by_name. Mention: LUAD EFO_0000571; SCLC likely EFO_0002618 or MONDO_0008433 — verify. Actually for Open Targets, SCLC might be EFO_0002618 "small cell lung carcinoma". I'll say "verify exact ID; do not substitute NSCLC (EFO_0003060?)".
> 
> Known B7-H3 agents (prior knowledge to seed clinical-trialist): ifinatamab deruxtecan (I-DXd, DS-7300), vobramitamab duocarmazine (MGC018), enoblituzumab (MGA271), omburtamab (8H9, radioimmunotherapy), DS-5573a? (bispecific), MGD009 (B7-H3 x CD3), ABBV-155 (B7-H3 ADC), 7-8002? Also "HS-20093" (B7-H3 ADC, GSK), "SHR-A2009"? Maybe. Tell clinical-trialist to search intervention names and mechanism terms.
> 
> Safety: B7-H3 is expressed broadly at low levels in normal tissues; omburtamab had CNS toxicity issues? Actually omburtamab (burtomab) intrathecal for neuroblastoma leptomeningeal metastases failed FDA ODAC. B7-H3 ADCs have interstitial lung disease/pneumonitis risk, myelosuppression, etc. Let specialist verify from FDA data. Note OpenFDA may not have these newer agents.
> 
> Genomics: CD276 is not a GWAS target for lung cancer; likely no 
> *... [5,378 chars total]*

> All seven specialists returned. Key findings:
> 
> 1. Genomics: ABSENT genetic evidence for LUAD/SCLC. CD276 locus is a pleiotropic liver-enzyme locus. Antibody tractable only.
> 2. Single-cell: LUAD — highest in fibroblasts/stroma (75.9 CPM), malignant 23.6; SCLC epithelial 28.5, below fibroblast 68.1, macrophage 48.8. Tumor vs normal: LUAD epithelial 2x higher in 3/3 donor pairs (underpowered). Normal tissue hotspots: skin, kidney, adrenal, adipose, colon, lung 13.9. Hematopoietic near zero. This is critical: B7-H3 expression is not tumor-cell-selective in scRNA — stroma highest. But caveat transcript vs protein; B7-H3 protein is known to be high on tumor cells. Still, this weakens a "tumor-cell-selective" narrative based on transcript. Need careful synthesis.
> 3. Functional genomics: no intrinsic dependency (expected), no selectivity. Tahoe unavailable (TAHOE_DATA_PATH not set) — gap.
> 4. Pathways: no Reactome annotation, no canonical receptor established, no high-confidence physical interactions. CD8A/IFNG textmining. Immune checkpoint context unresolved. LoF tolerant.
> 5. Clinical: 0 LUAD-specific trials; 26 SCLC-contributing trials; 6 Phase 3; ADCs dominate (I-DXd, HS-20093, MHB088C, YL201, MGC018, etc.). Only 4/43 trials posted results; MGC018 SCLC n=9 ORR 0/9. No LUAD-specific outcome. Strong target feasibility in SCLC, weak proven efficacy.
> 6. Safety: moderate risk; broad low-level normal expression; lung 1,683 TPM; macaque 94.6% identity vs mouse 52.4%; ADC class toxicities (ILD/pneumonitis); no FDA records for I-DXd/MGC018; enoblituzumab/omburtamab no warnings. LoF o/e 0.667.
> 7. Target biology: surface antigen, antibody tractable, no small molecule/PROTAC. Broad normal expression. Internalization/shedding not retrievable. Mouse poor tox species.
> 
> Now dispatch s8 (medchem-pharmacologist) with s5 and s7 summaries + paths. Then s9 reviewer with all outputs. I should also use TodoWrite to track (multi-step). Let me set up a todo list.
> 
> For s8, 
> *... [4,083 chars total]*

> Now dispatch the scientific reviewer with all 8 outputs. Provide summaries and exact paths. The reviewer has Read only, so paths are essential. Let me list the key artifacts:
> 
> s1 genomics:
> - work/genomics-analyst/results/reports/cd276_genetic_evidence.md
> - tables: cd276_luad_sclc_genetic_evidence? Actually returned names: cd276_disease_ids.csv, cd276_luad_sclc_study_cd276_locus_check.csv, cd276_luad_sclc_region_overlap_check.csv, cd276_l2g_predictions.csv, cd276_qtl_colocalization_summary.csv, cd276_region_credible_sets.csv, cd276_tractability.csv, cd276_prioritisation_scores.csv. Note plan expected cd276_luad_sclc_genetic_evidence.csv but agent didn't produce that exact name. For claims I must use actual paths. I'll verify via list_artifacts later.
> 
> s2 single-cell:
> - results/tables/cd276_luad_sclc_celltype_expression.csv
> - cd276_luad_sclc_lineage_expression.csv
> - cd276_epithelial_tumor_vs_normal_donor_paired.csv
> - cd276_key_comparisons.csv
> - cd276_normal_tissue_organ_summary.csv
> - cd276_normal_tissues_lineage_expression.csv
> - figures: cd276_luad_sclc_celltype_expression.png, cd276_luad_tumor_vs_normal_paired.png, cd276_normal_tissues_organ_by_lineage.png
> 
> s3 functional:
> - tables: cd276_depmap_luad_sclc.csv, cd276_depmap_group_summary.csv, cd276_depmap_group_comparisons.csv, cd276_depmap_disease_comparator.csv, cd276_depmap_gene_effect_bins.csv, cd276_histology_mapping.csv, cd276_tahoe_query_status.json
> - figure cd276_depmap_luad_sclc_distribution.png
> - report cd276_functional_genomics.md
> 
> s4 pathways:
> - results/tables/cd276_pathways_interactions.csv, cd276_constraint_tractability.csv, cd276_human_paralogues.csv
> - figures/cd276_partner_confidence.png
> - reports/cd276_pathway_safety.md
> 
> s5 clinical:
> - tables b7h3_luad_sclc_trials.csv, b7h3_luad_search_hits.csv, b7h3_posted_results_extract.csv, b7h3_ctgov_query_counts.csv, cd276_known_drugs_drug_mcp.csv, cd276_chembl_parquet_coverage.csv
> - figures/b7h3_phase_landsca
> *... [4,580 chars total]*

> The reviewer found important corrections:
> - Single-cell "2x adjacent normal in 3/3 donor pairs" is wrong: ratios 3.26, 3.40, 1.09 — only 2/3 reach 2x. So "3/3 direction" still true (all >1), but "2x in 3/3" false. The specialist summary said "higher in all 3 donor-matched pairs ... 27.0 vs 13.5 CPM donor means (2.0×)". Actually they said higher in all 3, 2.0x on donor means — reviewer says ratio of donor means is 2x but individual ratios are 3.26, 3.40, 1.09. So the direction is 3/3, but magnitude 2x only 2/3. I must state correctly: epithelial CD276 was higher in all 3 donor-matched LUAD pairs, but the fold-change was ≥2x in only 2/3 and the comparison was not statistically significant (n=3).
> 
> - "128 donors" not traceable (max per cell type 115). I'll avoid donor count or say ~128 donors from dataset metadata but per-cell-type max 115. Better to use dataset counts: 3 datasets, 636k cells. I can say 3 datasets/635,998 cells. Avoid donor count unless verified. Actually the single-cell report said 128 donors. Reviewer says "128 donors (max per-cell-type is 115)". I'll say "635,998 cells from 3 datasets" and for SCLC "31,540 cells from 1 dataset (9 donors)".
> 
> - p=0.22 not traceable — don't cite p-value.
> 
> - SCLC GO premature — stage on ARTEMIS-008; "6 Phase 3" is 6 trials / 4 molecules (I-DXd, HS-20093, MHB088C, YL201 — yes 4 molecules).
> - LUAD NO-GO defensible as strategy, not science; clinical precedence scored 1; LUAD patients enrolled in nonsquamous NSCLC trials (NCT07464327, NCT06780085, NCT07824882).
> - Stromal finding apply symmetrically (SCLC also fibroblast > epithelial).
> - Normal lung: RNA level 4 but protein level 2; Census cell-level transcript among lowest organs. So "high lung expression" overstates protein-level risk. Need careful: HPA bulk lung 1,683 TPM (level 4 RNA), but protein level 2 and Census normal lung 13.9 CPM. So lung expression is moderate, not highest. The safety concern remains but should be qualified.
> - LoF CI: 90% vs 
> *... [8,899 chars total]*

> The medchem revision succeeded. The single-cell and fda revisions failed with transient 403 authentication errors. The system prompt says retry a few times, restating with clear intent. Let me retry both. The failures produced agent IDs but no work. I'll re-issue the same tasks (new agents). Maybe the 403 was transient. Let me retry both in parallel.
> 
> Before retrying, note that the single-cell report still contains the incorrect claim. I need the correction to cite the artifact accurately. Let me retry.
> 
> Also, I should now start preparing the claims. But first get revisions.
> 
> Retry prompts, maybe slightly shorter to reduce load. Include explicit "This is a retry; a prior attempt failed with a transient 403."
> 
> Let me retry.

> All revisions complete. Now I need to:
> 1. Update todo list.
> 2. Get exact artifact paths via mcp__provenance__list_artifacts (required before record_claims).
> 3. Verify key files exist / maybe read tables to confirm numbers.
> 4. Draft synthesis with [[claim:Cn]] anchors.
> 5. Call record_claims.
> 6. Write final report? The run-organization says report/FINAL_REPORT.md is generated? It says report/FINAL_REPORT.md in layout; MANIFEST/README/audit are generated. It doesn't explicitly say FINAL_REPORT is generated. The end-of-run checklist doesn't mention writing it, but layout includes it. As CSO, I likely should write the final report to report/FINAL_REPORT.md. The system prompt says outputs: inputs/plan.json and evidence/claims.json are not optional. FINAL_REPORT likely generated by harness from my response, or I should write it. Hmm. The run-organization layout shows report/FINAL_REPORT.md. It may be generated at the end from the transcript. To be safe, I'll write a polished FINAL_REPORT.md — it's a session file, allowed. But the instruction "NEVER create documentation files unless explicitly requested" conflicts; however run-organization explicitly includes report/FINAL_REPORT.md in the run structure and the audit trail requires it. I'll write it. Actually, the skill says "MANIFEST.json, provenance.json, README.md and audit.html are generated. Your two responsibilities are plan.json and claims.json." It doesn't say FINAL_REPORT is generated, so probably the CSO writes it. I'll write it after claims.
> 
> First, list artifacts. The mcp__provenance__list_artifacts tool is available (I used write_plan successfully). Let me call it. Maybe filter by agent? I can list all. It may return many artifacts. Let me call with no filter and inspect. It might be large but manageable.
> 
> Also update todos.
> 
> Let me call list_artifacts and TodoWrite in parallel.

> 208 artifacts. I need exact paths for the ones I will cite. Rather than parse 57KB, let me use the saved output file and grep for the specific files. I can Read the saved file or use Grep. Let me grep for key filenames in the tool-results file. The file is at /home/xqinag/.claude/projects/.../tool-results/call_01_cRW4FYr5Dx6A88tFgiuh0197.txt.
> 
> Let me use Bash with python to parse JSON and list paths for each agent's key artifacts. Or Grep for "results/reports" etc. Better: use python to load JSON and print path, kind, description (truncated) for artifacts where path contains selected keywords. This is not scientific analysis, just file management — allowed.
> 
> Let me run a python snippet (Bash) reading the JSON file. Use only preinstalled python. Fine.
> 
> I want paths for:
> - genomics report + key tables
> - single-cell corrected tables/report
> - functional tables/report
> - pathway tables/report
> - clinical tables/report
> - safety tables/report
> - target biologist tables/report
> - medchem corrected tables/report
> - reviewer report
> 
> Let me print all "report" kind paths and key table paths. Then I'll select.
> 
> Command:
> python - <<'EOF'
> import json
> d=json.load(open(path))
> for a in d['artifacts']:
>     p=a['path']
>     if a['kind'] in ('report',) or p.endswith(('.csv','.png')) and any(k in p for k in ['cd276','b7h3']):
>         print(p, '|', a['kind'], '|', (a.get('description') or '')[:120])
> EOF
> 
> That will be many but manageable (maybe 100). Let me limit to reports + selected tables. Actually I need exact paths for claims. Let me print all cd276/b7h3 artifacts with descriptions. I'll then pick.
> 
> Let me run it.

> I now have exact paths. I need to file claims. Let me plan the synthesis and claims.
> 
> Key claims to file (each with evidence):
> 
> C1: CD276 is a cell-surface antigen with strong antibody tractability and no small-molecule/PROTAC tractability. Evidence: target-biologist table cd276_tractability_by_modality.csv; target biology csv.
> C2: No intrinsic CRISPR dependency in LUAD (n=46, mean -0.230, 1/46 essential) or SCLC (n=25, mean -0.204, 0% essential), no lineage selectivity. Evidence: functional tables.
> C3: No genetic association of CD276 with LUAD or SCLC: 0/8 studies with CD276-locus credible set; 67 L2G all non-LUAD/SCLC. Evidence: genomics tables.
> C4: CD276 transcript in LUAD is highest in fibroblasts (75.9 CPM) and macrophages (33.5) vs malignant (23.6); SCLC epithelial 28.5 vs fibroblast 68.1. Evidence: single-cell tables.
> C5: LUAD tumor epithelium higher than paired adjacent normal in 3/3 donors, ≥2x in 2/3 (3.26, 3.40, 1.09), n=3 not significant. Evidence: paired summary/stats.
> C6: Normal tissue expression broad and low-to-moderate; skin/kidney highest; hematopoietic near zero; normal lung RNA 1,683 TPM (HPA level 4) but protein level 2 and Census transcript 13.9 CPM. Evidence: single-cell normal organ summary + fda expression evidence + medchem qualification.
> C7: Clinical landscape: 0 LUAD-specific B7-H3 trials; 26 SCLC-contributing trials, 6 Phase 3 across 4 molecules; ADCs dominate. Evidence: clinical tables.
> C8: Only 4/43 trials have posted results; only SCLC-specific posted result MGC018 n=9 ORR 0/9; no LUAD-specific outcome. Evidence: posted results extract.
> C9: No proven efficacy in either indication; SCLC feasibility established, efficacy unproven; ARTEMIS-008 completed without posted results. Evidence: clinical report/table. Hmm, ARTEMIS-008 completed with no results — where is that in evidence? b7h3_luad_sclc_trials.csv likely has status. I can cite that table.
> C10: Safety: CD276 LoF o/e 0.667 (moderate tolerance); no OpenFDA 
> *... [14,084 chars total]*

> All 15 claims recorded with evidence verified. Now write the final synthesis. Should I also write report/FINAL_REPORT.md? Let me do that, then give the final response. The report should match the synthesis. I'll write a concise but complete report with claim anchors. Then final response summarizes.
> 
> Let me write FINAL_REPORT.md. Include:
> - Title, date, scope
> - Executive decision
> - Evidence by domain with claim anchors
> - Modality ranking table
> - Go/no-go gates
> - Evidence gaps
> - Confidence
> - Artifact index
> 
> Use the claim anchors [[claim:Cn]]. The report is a file; anchors render in the UI? The claim anchors are for the response. In the file, they're still useful as references. Fine.
> 
> Let me be careful about factual precision:
> - LUAD: 635,998 cells from 3 datasets; SCLC 31,540 cells from 1 dataset/9 donors.
> - CD276 transcript: LUAD fibroblast 75.9, malignant 23.6; macrophage 33.5 (lineage table says macrophage 33.5; earlier summary said 32.9/33.8 depending label). Use 33.5 from lineage table.
> - SCLC epithelial 28.5, fibroblast 68.1.
> - Tumor vs normal: 3.26, 3.40, 1.09; 3/3 higher, 2/3 ≥2x, n=3, p=0.222 (but reviewer said don't quote p unless artifact; now there is cd276_luad_paired_donor_stats.csv with p=0.222, so I can mention not significant without p, or cite p. I'll say "not statistically significant (n=3)" and avoid the p-value to keep clean.)
> - Normal lung: 1,683 TPM bulk RNA level 4, protein level 2, Census 13.9 CPM.
> - Genetics: 0/8 studies; 0/67 L2G from LUAD/SCLC.
> - DepMap: LUAD n=46 mean -0.230, 1/46 essential; SCLC n=25 mean -0.204, 0% essential.
> - Clinical: 0 LUAD-specific; 26 SCLC-contributing; 6 Phase 3 across 4 molecules; 43 curated; 4 posted results; MGC018 n=9 ORR 0/9; ARTEMIS-008 completed no results.
> - Safety: LoF o/e 0.667; no target-level AE/mouse/PGx records; no FDA records for I-DXd/MGC018; enoblituzumab/omburtamab 0 warnings (unapproved); macaque 94.6% vs mouse 52.4% identity.
> - Modality: SCLC ADC 
> *... [5,097 chars total]*

> Now write FINAL_REPORT.md. Let me craft a polished report. It should be comprehensive but not bloated. Then final response with synthesis and next steps.
> 
> I'll write the report to report/FINAL_REPORT.md. Use Write. Need to ensure directory exists (it does). Then final answer.
> 
> Let me draft the report content.
> 
> # B7-H3 (CD276) Therapeutic Candidacy in LUAD and SCLC
> Run ID, date, scope, decision summary.
> 
> Sections:
> 1. Decision summary
> 2. Target biology / rationale
> 3. Genetic and functional evidence
> 4. Expression and selectivity
> 5. Clinical precedence
> 6. Safety
> 7. Modality ranking
> 8. Go/no-go gates and decisive experiment
> 9. Evidence gaps and confidence
> 10. Artifact map
> 11. Prior knowledge disclosures
> 
> Use claim anchors. Keep it readable.
> 
> One consideration: The report is written by the CSO; it's a synthesis, not analysis. Fine.
> 
> Let me write it.

> Now update todo and give final response. The final response should be a crisp synthesis with claim anchors, then "Suggested next steps". Since the user asked for an evaluation, I should deliver the decision clearly. Keep it executive-level but substantive. The report is written; I can point to it.
> 
> Need to include anchors [[claim:Cn]] inline. Keep response maybe 700-1000 words? The system says concise. But this is a substantive scientific evaluation. I'll provide a structured summary of ~700 words plus next steps.
> 
> Let me update todo to completed, then final answer. TodoWrite can be in same message? I'll call it, then respond. Actually, I can call TodoWrite and then text in the same assistant turn? Tool calls and text can be combined. Better: call TodoWrite, then final text. The tool call will execute and then I'll write. Since I need to produce final text after, I can do tool call now and then after result, text. But that's an extra round trip. I can include text after tool call in the same message? The format allows multiple tool calls and text. However, the tool result comes after. Usually I call TodoWrite and then in the next turn write. That's fine. But to be efficient, I could skip TodoWrite and just write final answer — but the todo is in_progress; good practice to mark complete. Let me call TodoWrite now.
> 
> Then final response.

> Now write the final response. Include:
> - Bottom line
> - Evidence summary per domain with claims
> - Modality ranking
> - Decision + gates
> - Gaps
> - Suggested next steps (2-4)
> 
> Keep it tight but complete. Use headers and a table. Ensure every substantive factual assertion has an anchor where appropriate. Not every sentence needs one; group.
> 
> Let me draft.
> 
> Bottom line: B7-H3 is a credible ADC target in SCLC, not yet a validated one; LUAD deprioritized.
> 
> Key points:
> 1. Biology: surface antigen, antibody-tractable, no SM/PROTAC [[C1]]; no intrinsic dependency [[C2]]; no receptor established [[C14]] → payload delivery.
> 2. Genetics absent [[C3]] → rationale is expression, not genetics.
> 3. Expression: stromal > malignant in both [[C4]]; LUAD tumor vs normal direction 3/3 but 2/3 ≥2x, n=3 [[C5]]; normal tissue broad, lung protein level 2 [[C6]]; caveat transcript not protein.
> 4. Clinical: 0 LUAD-specific, 26 SCLC trials, 6 Phase 3/4 molecules [[C7]]; only 4/43 posted results, MGC018 0/9, ARTEMIS-008 no results [[C8]]; LUAD eligible in 3 NSCLC trials [[C16]] → feasibility not efficacy.
> 5. Safety: LoF o/e 0.667, gaps [[C10]]; payload ILD/myelosuppression dominant [[C11]]; mouse poor tox species [[C17]].
> 6. Modality: ADC rank 1; SCLC staged GO 4.20, LUAD deprioritized 2.90/1/5 [[C12]].
> 7. Gates/decisive experiment [[C13]].
> 8. Gaps [[C15]].
> 
> Suggested next steps:
> 1. Commission the decisive paired IHC/flow surface-density + internalization study in ≥20 SCLC and LUAD resections vs normal lung — resolves the central unknown.
> 2. Build a differentiation strategy for the SCLC ADC (novel payload/linker or DLL3 TCE combination) — me-too not investable.
> 3. Track first Phase 3 OS readout (ARTEMIS-008 / I-DXd) — gate for any SCLC commitment.
> 4. If LUAD is strategic, scope a TROP2/HER3 benchmark and biomarker-defined niche before committing.
> 
> Ask which to pursue.
> 
> Mention report path. Also note the scientific reviewer forced correc
> *... [2,304 chars total]*

### Sub-agent Traces
- **fda-safety-officer** — 217.02s (117 messages)
- **target-biologist** — 345.39s (126 messages)
- **functional-genomics-analyst** — 388.41s (171 messages)
- **bio-pathways-ppi-analyst** — 494.0s (225 messages)
- **genomics-analyst** — 503.86s (206 messages)
- **clinical-trialist** — 1148.64s (373 messages)
- **single-cell-analyst** — 8297.19s (400 messages)
- **medchem-pharmacologist** — 855.76s (228 messages)
- **scientific-reviewer** — 251.42s (77 messages)
- **medchem-pharmacologist** — 670.45s (223 messages)
- **fda-safety-officer** — 392.95s (157 messages)
- **single-cell-analyst** — 448.84s (174 messages)
